Novartis Ireland Limited is the Irish affiliate of Swiss-based Novartis AG – one of the largest and most widely respected pharmaceutical companies in the world.
Reflecting our commitment to innovation, 18% of pharma net sales is invested back into research and development, focusing on the areas of greatest patient need and scientific promise1.
Novartis is one of Ireland’s leading employers in the healthcare industry. One of the first pharmaceutical companies to locate in Ireland in the 1950’s, Novartis has a strong history of investing in Ireland over the last sixty years.
Novartis employs approximately 1,600 people across 3 locations in Cork and Dublin. Novartis manufacturing and development is based in Ringaskiddy, Co Cork. Alcon, located on the Model Farm road is the leading manufacturer of technologies used to treat cataracts. In March 2013 Novartis announced the establishment of a Global Business Services Center in Elm Park. Novartis Pharmaceuticals is also based in Elm Park.
The Irish Pharmaceutical industry currently generates over 50 percent of the country’s exports contributing to making Ireland the largest net exporter of medicines in the EU. 9 of the top 10 pharma companies in the world are located in Ireland. The industry directly employs over 24,500 people, over half of which are third level graduates.
Novartis Commercial Operations
Novartis has six healthcare priorities: Respiratory, Neuroscience, Cardiology, Dermatology & Rheumatology, Eyecare and Oncology. Novartis has been recognised as having one of the best pipelines in the world. Novartis is the number one pharmaceutical company involved in clinical trials in Ireland. Two thirds of our key Dublin suppliers are either Irish or based in Dublin2. For more information on our products, please go to www.medicines.ie
Novartis Global Services Center
The Novartis Global Service Center (NGSC), Dublin, was set up in 2013 and is located in a state-of-the-art facility in Ballsbridge. The center, one of five around the world, delivers a broad variety of services to the Novartis divisions and organisations globally.
Services offered by the Dublin team include scientific and commercial services, IT, HR Services and Procurement.
NGSC Dublin has a deep talent pool driving innovation, standardisation and world-class service delivery. There are currently more than 500 associates employed at the site with 38 nationalities speaking 29 languages. Almost half of the associates are educated to master’s degree level while 17 per cent hold a PhD.
Technical and Chemical Operations at Novartis Ringaskiddy
Novartis Ringaskiddy is home to two Novartis organisations and approximately 600 employees, Novartis Ringaskiddy Ltd (NRL), a Chemical Operations manufacturing facility and Novartis International Pharmaceutical Ltd, Branch Ireland (NIPBI) a supply organisation for Technical Operations.
Operational since 1994, NRL manufactures active pharmaceutical ingredients for a range of oncology, respiratory cardiovascular, dermatology, central nervous systems and transplantation medicines.
Established in 1998, NIPBI is a global service centre offering technical and business services through a number of functions including; External Supply Operation, International Service Laboratory, Supply Chain, Procurement, Finance and Strategy.
IDA Ireland published this short video on Novartis Ringaskiddy. Novartis Ringaskiddy is home to both the manufacturing site, Novartis Ringaskiddy Limited which manufactures active pharmaceutical ingredients for a range of cancer, respiratory, heart, dermatology, neurology and transplant medicines and to Novartis International Pharmaceutical Ltd., a global supply organization. Established over twenty years ago the Novartis Ringaskiddy campus is proud to be part of a unique pharma cluster in Cork with nine life sciences companies located in the region.
Approximately 400 associates work at the Alcon Cork facility. In 2011 Novartis fully acquired Alcon, making it the world’s number one eye care company. In 2016, Alcon celebrated 25 years operating in Ireland.
The plant manufactures Alcon’s AcrySof® intraocular lenses (IOLs), which replace the eye’s natural lens in cataract surgery. Alcon’s AcrySof® IOLs are the most frequently implanted lenses worldwide, with more than 90 million implants since their introduction in the mid-1990s.